Granite Point Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Granite Point Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-550,000	Closed	-$49.4M	–	142
2022 Q1	$49.4M	Buy	550,000 +400,000	+267%	+$36.9M	10.32%	2
2021 Q4	$16.8M	Buy	+150,000	New	+$18.1M	2.84%	5
2021 Q3	–	Sell	-200,000	Closed	-$27.1M	–	182
2021 Q2	$27.1M	Buy	+200,000	New	+$26.3M	1%	6
2019 Q1	–	Sell	-100,000	Closed	-$7.17M	–	136
2018 Q4	$7.17M	Buy	+100,000	New	+$8.06M	1.45%	12

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return

Granite Point Capital Management's XBI Position: Q2 2023 in Review

Granite Point Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2023, closing a stake of 3,000 shares — an estimated $229K sold.

Granite Point Capital Management first reported a position in XBI in Q2 2022 and held it in 4 quarters. The position peaked at $1.19M in Q3 2022. 713 funds tracked by Wall St. Rank hold XBI as of Q2 2023.

Granite Point Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2023 after selling out during the quarter.
Granite Point Capital Management sold 3,000 State Street SPDR S&P Biotech ETF shares in Q2 2023, an estimated $229K.
Granite Point Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 4 quarters.
Granite Point Capital Management's State Street SPDR S&P Biotech ETF position peaked at $1.19M in Q3 2022.
713 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2023.

Based on Granite Point Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.